Browse by Title

Type here to filter the list

N
Newly Diagnosed Multiple Myeloma

Maria-Victoria Mateos, PhD (she/her/hers) – University Hospital of Salamanca ### 1949876###Chair###Head of Unit###University Hospital of Salamanca###
Chair: Maria-Victoria Mateos, PhD (she/her/hers) – University Hospital of Salamanca
### she/her/hers @@@ S. Vincent Rajkumar, MD – Mayo Clinic ### 1949877###Co-Chair###Edward W. and Betty Knight Scripps Professor of Medicine###Mayo Clinic###
Co-Chair: S. Vincent Rajkumar, MD – Mayo Clinic
###
Non-Immune therapy for TCR

Paula Rodriguez-Otero, MD PhD (she/her/hers) – Clinica Universidad de Navarra ### 1949883###Speaker###Consultant in Hematology ###Clinica Universidad de Navarra ###
Speaker: Paula Rodriguez-Otero, MD PhD (she/her/hers) – Clinica Universidad de Navarra
### she/her/hers
Novel in vivo models of myeloma origin

Karin Vanderkerken, PhD (she/her/hers) – Vrije Universiteit Brusssels ### 1949874###Speaker###full professor###Vrije Universiteit Brusssels###
Speaker: Karin Vanderkerken, PhD (she/her/hers) – Vrije Universiteit Brusssels
### she/her/hers
Novel Technology and Insights in MM

Kenneth C. Anderson, MD – The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA ### 1395077###Chair###Professor in Medicine###The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA###
Chair: Kenneth C. Anderson, MD – The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
### @@@ Gareth Morgan, MD, PHD, FRCP, FRCPATH (he/him/his) – NYU Langone Health Perlmutter Cancer Center ### 1395144###Co-Chair###Professor of Medicine, Director of Myeloma Research###NYU Langone Health Perlmutter Cancer Center###
Co-Chair: Gareth Morgan, MD, PHD, FRCP, FRCPATH (he/him/his) – NYU Langone Health Perlmutter Cancer Center
### he/him/his
NSO-01: Real world experience of teclistamab using a prompt management strategy for cytokine release syndrome

Donna D. Catamero, ANP-BC – Mount Sinai Hospital ### 1442247###Speaker###Nurse Practitioner###Mount Sinai Hospital###
Speaker: Donna D. Catamero, ANP-BC – Mount Sinai Hospital
###
NSO-02: Characteristics of Multiple Myeloma Patients with Central Nervous System Involvement

Jessica Chen, MS, FNP – MD Anderson Cancer Center ### 2076077###Speaker###Nurse Practitioner###MD Anderson Cancer Center###
Speaker: Jessica Chen, MS, FNP – MD Anderson Cancer Center
###
NSO-03: Impact of Myeloma and Amyloidosis on young patients

Emma Dowling, RN BSC – HCA Healthcare UK ### 1442039###Speaker###Myeloma Clinical nurse specialist###HCA Healthcare UK###
Speaker: Emma Dowling, RN BSC – HCA Healthcare UK
###
NSO-04: Characterising sleep disturbances with actigraphy in those receiving steroids for the treatment of multiple myeloma: Findings from a pilot study

Tracy King, PhD, MN, RN – Royal Prince Alfred Hospital, The University of Sydney ### 1408995###Speaker###Myeloma Nurse Consultant, Clinical Associate Professor###Royal Prince Alfred Hospital, The University of Sydney###
Speaker: Tracy King, PhD, MN, RN – Royal Prince Alfred Hospital, The University of Sydney
###
NSO-05: Specialist physiotherapy post-autologous stem cell transplant improved functional outcomes with high patient satisfaction in multiple myeloma patients

Joanne S. Land, BSc (she/her/hers) – NHS University College London Hospital, London, United Kingdom ### 2076076###Speaker###Clinical Specialist Myeloma Physiotherapist###NHS University College London Hospital, London, United Kingdom###
Speaker: Joanne S. Land, BSc (she/her/hers) – NHS University College London Hospital, London, United Kingdom
### she/her/hers
NSO-06: ‘Just one thing’: patient, nurse and haematologist priorities for myeloma services

Monica Morris, MSc, RN – Myeloma UK ### 1408999###Speaker###Clinical Practice Services ###Myeloma UK###
Speaker: Monica Morris, MSc, RN – Myeloma UK
###
NSO-07: Management Considerations for Dermatologic Toxicities Associated With Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

Chloe Ray, AGPCNP-BC, OCN – Mount Sinai Hospital ### 2082047###Speaker###Clinical Research Nurse Practitioner###Mount Sinai Hospital###
Speaker: Chloe Ray, AGPCNP-BC, OCN – Mount Sinai Hospital
###